$314.43K in average volume shows that Harvard Bioscience Inc (HBIO) is heading in the right direction

On Tuesday, Harvard Bioscience Inc (NASDAQ: HBIO) opened higher 4.24% from the last session, before settling in for the closing price of $0.57. Price fluctuations for HBIO have ranged from $0.56 to $4.70 over the past 52 weeks.

Healthcare Sector giant saw their annual sales slid by -3.49% over the last five years. Company’s average yearly earnings per share was noted 50.00% at the time writing. With a float of $38.01 million, this company’s outstanding shares have now reached $44.07 million.

The firm has a total of 355 workers. Let’s measure their productivity. In terms of profitability, gross margin is 55.35%, operating margin of -5.31%, and the pretax margin is -12.39%.

Harvard Bioscience Inc (HBIO) Insider Activity

A key investor’s attitude towards the stock of the Medical Instruments & Supplies industry is another important factor to consider. The insider ownership of Harvard Bioscience Inc is 13.77%, while institutional ownership is 72.28%. The most recent insider transaction that took place on Jun 13 ’24, was worth 29,100. In this transaction Chief Executive Officer of this company bought 10,000 shares at a rate of $2.91, taking the stock ownership to the 3,111,091 shares. Before that another transaction happened on Jun 06 ’24, when Company’s Chief Executive Officer bought 20,000 for $3.07, making the entire transaction worth $61,400. This insider now owns 3,101,091 shares in total.

Harvard Bioscience Inc (HBIO) Earnings and Forecasts

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.0 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 50.00% per share during the next fiscal year.

Harvard Bioscience Inc (NASDAQ: HBIO) Trading Performance Indicators

Check out the current performance indicators for Harvard Bioscience Inc (HBIO). In the past quarter, the stock posted a quick ratio of 0.40. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.28.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.29, a number that is poised to hit -0.04 in the next quarter and is forecasted to reach 0.07 in one year’s time.

Technical Analysis of Harvard Bioscience Inc (HBIO)

Analysing the last 5-days average volume posted by the [Harvard Bioscience Inc, HBIO], we can find that recorded value of 0.32 million was better than the volume posted last year of 0.32 million. As of the previous 9 days, the stock’s Stochastic %D was 18.03%. Additionally, its Average True Range was 0.07.

During the past 100 days, Harvard Bioscience Inc’s (HBIO) raw stochastic average was set at 1.33%, which indicates a significant decrease from 17.65% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 67.34% in the past 14 days, which was lower than the 77.39% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $1.1003, while its 200-day Moving Average is $2.2234. Now, the first resistance to watch is $0.6509. This is followed by the second major resistance level at $0.7119. The third major resistance level sits at $0.7538. If the price goes on to break the first support level at $0.5480, it is likely to go to the next support level at $0.5061. Should the price break the second support level, the third support level stands at $0.4451.

Harvard Bioscience Inc (NASDAQ: HBIO) Key Stats

There are currently 44,074K shares outstanding in the company with a market cap of 26.00 million. Presently, the company’s annual sales total 94,140 K according to its annual income of -12,410 K. Last quarter, the company’s sales amounted to 24,560 K and its income totaled 20 K.